Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iscador A is a fermented plant-based extract derived from mistletoe (*Viscum album*) grown on fir trees (*Abies*). Developed as an anthroposophic medicinal product, it is used in integrative oncology as an adjuvant therapy for various types of cancer. Administered via subcutaneous injection, Iscador A is designed to stimulate the immune system and exert direct cytotoxic effects on tumor cells. The extract contains pharmacologically active constituents, including mistletoe lectins, which are known to inhibit protein synthesis by targeting ribosomes, and viscotoxins, which induce cell membrane damage. It is widely prescribed in German-speaking European countries to improve the quality of life and reduce the side effects of conventional treatments like chemotherapy and radiation, although it is not approved by the U.S. FDA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Iscador A.